BIRT 2584 XX

Drug Profile

BIRT 2584 XX

Alternative Names: BIRT 2584; BIRT2584XX; integrin inhibitors - Boehringer Ingelheim

Latest Information Update: 08 Nov 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action Integrin alpha chain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Psoriasis

Most Recent Events

  • 03 May 2007 Discontinued - Phase-II for Psoriasis in Canada (PO)
  • 03 May 2007 Discontinued - Phase-II for Psoriasis in European Union (PO)
  • 15 Jan 2007 Discontinued - Phase-II for Multiple sclerosis in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top